{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:50:12Z","timestamp":1790740212081,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003351","name":"Fundaci\u00f3n para la Formaci\u00f3n y la Investigaci\u00f3n de los Profesionales de la Salud de Extremadura","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ijid.2019.07.008","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T11:45:38Z","timestamp":1563536738000},"page":"142-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0743-8182","authenticated-orcid":false,"given":"D.V.","family":"P\u00e9rez Civantos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Robles Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Azanza Perea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pazos Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Garc\u00eda-Montoto P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Jerez G\u00f3mez-Coronado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"June (6)","key":"10.1016\/j.ijid.2019.07.008_bib0005","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/jac\/dkt542","article-title":"Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration","volume":"69","author":"Aguilar","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"March (2)","key":"10.1016\/j.ijid.2019.07.008_bib0010","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/cc13805","article-title":"Pharmacokinetics of anidulafungin during albumin dialysis","volume":"18","author":"Aguilar","year":"2014","journal-title":"Crit Care"},{"issue":"January (2)","key":"10.1016\/j.ijid.2019.07.008_bib0015","article-title":"Pharmacokinetics of anidulafungin in critically ill intensive care unit patients with suspected or proven invasive fungal infections","volume":"61","author":"Br\u00fcggemann","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2019.07.008_bib0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijantimicag.2009.03.003","article-title":"Extended daily dialysis does not affect the pharmacokinetics of anidulafungin","volume":"34","author":"Burkhardt","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 7","key":"10.1016\/j.ijid.2019.07.008_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2019.07.008_bib0030","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1179\/1973947813Y.0000000089","article-title":"Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH","volume":"25","author":"De Rosa","year":"2013","journal-title":"J Chemother"},{"key":"10.1016\/j.ijid.2019.07.008_bib0035","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s15010-009-8249-6","article-title":"The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis","volume":"37","author":"de Ruiter","year":"2009","journal-title":"Infection"},{"key":"10.1016\/j.ijid.2019.07.008_bib0040","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijantimicag.2012.07.018","article-title":"Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis","volume":"40","author":"Dimopoulos","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"February (2)","key":"10.1016\/j.ijid.2019.07.008_bib0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0091270004270146","article-title":"Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine","volume":"45","author":"Dowell","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"April (4)","key":"10.1016\/j.ijid.2019.07.008_bib0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0091270006297227","article-title":"Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment","volume":"47","author":"Dowell","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2019.07.008_bib0055","series-title":"Ficha T\u00e9cnica Anidulafungina. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Junio","author":"Ecalta","year":"2018"},{"issue":"October (10)","key":"10.1016\/j.ijid.2019.07.008_bib0060","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijid.2019.07.008_bib0065","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00134-014-3281-0","article-title":"What\u2019s new in the clinical and diagnostic management of invasive candidiasis in critically ill patients","volume":"40","author":"Le\u00f3n","year":"2014","journal-title":"Intensive Care Med"},{"issue":"April (4)","key":"10.1016\/j.ijid.2019.07.008_bib0070","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/AAC.02139-12","article-title":"Pharmacokinetics of anidulafungin in critically ill patients with candidemia\/invasive candidiasis","volume":"57","author":"Liu","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2019.07.008_bib0075","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/01.CCM.0000201889.39443.D2","article-title":"Candida as a risk factor for mortality in peritonitis","volume":"34","author":"Montravers","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijid.2019.07.008_bib0080","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1007\/s00134-013-3134-2","article-title":"Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis","volume":"39","author":"Montravers","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijid.2019.07.008_bib0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/11315560-000000000-00000","article-title":"Anidulafungin, a new echinocandin: in vitro activity","volume":"69 Suppl 1","author":"Morace","year":"2009","journal-title":"Drugs"},{"issue":"November (11)","key":"10.1016\/j.ijid.2019.07.008_bib0090","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/JCM.43.11.5425-5427.2005","article-title":"In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole","volume":"43","author":"Pfaller","year":"2005","journal-title":"J Clin Microbiol"},{"issue":"January (1)","key":"10.1016\/j.ijid.2019.07.008_bib0095","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/JCM.01901-07","article-title":"In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"issue":"August (8)","key":"10.1016\/j.ijid.2019.07.008_bib0100","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1128\/AAC.00323-08","article-title":"In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates","volume":"52","author":"Ruan","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2019.07.008_bib0105","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1469-0691.2012.03784.x","article-title":"Anidulafungin for the treatment of candidaemia\/invasive candidiasis in selected critically ill patients","volume":"18","author":"Ruhnke","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"February","key":"10.1016\/j.ijid.2019.07.008_bib0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","article-title":"Pharmacokinetic variability and exposures of fluconazole, anidulafungin and caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (DALI) patients study","volume":"19","author":"Sinnollareddy","year":"2015","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.ijid.2019.07.008_bib0115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1128\/AAC.01607-13","article-title":"Low but sufficient anidulafungin exposure in critically ill patients","volume":"58","author":"van Wanrooy","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"July (7)","key":"10.1016\/j.ijid.2019.07.008_bib0120","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (sepsis-related organ faillure assessment) score to describe organ dysfunction\/faillure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"issue":"June (7)","key":"10.1016\/j.ijid.2019.07.008_bib0125","article-title":"Pharmacokinetics of anidulafungin in obese and normal-weight adults","volume":"62","author":"Wasmann","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"March (4)","key":"10.1016\/j.ijid.2019.07.008_bib0130","article-title":"Anidulafungin pharmacokinetics in ascites fluid and pleural effusion of critically ill patients","volume":"62","author":"Welte","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219302930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219302930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:46:43Z","timestamp":1761119203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971219302930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":26,"alternative-id":["S1201971219302930"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2019.07.008","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2019.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}